Phase 1Recruiting

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

About this study

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Enrolling at this location

Taylor Cancer Research Center (site 204)

Maumee, Ohio

I'm interested

This study also enrolls at 13 other locations. See all.

Study details

Conditions

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung CancerNon-Small Cell Lung CancerPancreatic CancerMesotheliomaEsophageal CancerAny Solid Tumors Progressed After a Prior ImmunotherapyHead and Neck Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma HNSCCSalivary Gland CarcinomasHead and Neck Cancers - Salivary GlandHead and Neck Cancers - NasopharyngealHead and Neck Cancers - ThroatSmall Cell Lung Cancer ( SCLC )Lung Cancer (Locally Advanced or Metastatic)Head and Neck Cancers - TonsilsHead and Neck Cancers HypopharynxHead and Neck Cancers LarynxHead and Neck Cancers LipHead and Neck Cancers NasopharynxHead and Neck Cancers Oral CavityHead and Neck CancersHead and Neck Cancers OropharynxHead and Neck Cancers Trachea

Phase

Phase 1

Age

18–80 years old

Gender

All genders welcome

Healthy volunteers

Not accepted

Last updated

Dec 2025

NCT ID

NCT03556228

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.